May 14, 2015
The Central Social Insurance Medical Council (Chuikyo) approved the listing of 16 active pharmaceutical ingredients/28 products on May 13. Of those, five drugs including Gilead Sciences’s oral hepatitis C drug Sovaldi (sofosbuvir) are expected to record peak annual sales of...read more